# Clazosentan in Aneurysmal Subarachnoid Hemorrhage

> **NCT00940095** · PHASE3 · TERMINATED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 577 (actual)

## Conditions studied

- Aneurysmal Subarachnoid Hemorrhage

## Interventions

- **DRUG:** Clazosentan 5 m/h
- **DRUG:** Clazosentan 15 mg/h
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00940095
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-01
- **Primary completion:** 2010-10-01
- **Final completion:** 2011-01-01
- **Target enrollment:** 577 (ACTUAL)
- **Why stopped:** Lack of efficacy data from the Phase 3 clinical study (AC-054-301; CONSCIOUS-2)
- **Last updated:** 2018-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940095, "Clazosentan in Aneurysmal Subarachnoid Hemorrhage". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00940095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*